 Oncogene Proteins, Fusion
"Oncogene Proteins, Fusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
| Descriptor ID |
D015514
|
| MeSH Number(s) |
D12.776.602.500.500 D12.776.624.664.500
|
| Concept/Terms |
Oncogene Proteins, Fusion- Oncogene Proteins, Fusion
- Fusion Oncogene Proteins
- Proteins, Fusion Oncogene
- Oncogene Proteins, Chimeric
- Fusion Proteins, Oncogene
- Oncogene Fusion Proteins
- Proteins, Oncogene Fusion
- Chimeric Oncogene Proteins
- Proteins, Chimeric Oncogene
- Chimeric Proteins, Oncogene
- Oncogene Chimeric Proteins
- Proteins, Oncogene Chimeric
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins, Fusion".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins, Fusion".
This graph shows the total number of publications written about "Oncogene Proteins, Fusion" by people in this website by year, and whether "Oncogene Proteins, Fusion" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 2 | 0 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 2 | 3 | | 2010 | 2 | 3 | 5 | | 2011 | 1 | 1 | 2 | | 2012 | 4 | 2 | 6 | | 2013 | 2 | 5 | 7 | | 2014 | 4 | 2 | 6 | | 2015 | 3 | 1 | 4 | | 2016 | 3 | 3 | 6 | | 2017 | 6 | 3 | 9 | | 2018 | 4 | 5 | 9 | | 2019 | 8 | 2 | 10 | | 2020 | 5 | 3 | 8 | | 2021 | 6 | 2 | 8 | | 2022 | 0 | 5 | 5 | | 2023 | 0 | 2 | 2 | | 2024 | 3 | 6 | 9 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Oncogene Proteins, Fusion" by people in Profiles.
-
Roy SF, Agim NG, Mir A, Couts KL, Vandergriff T, Robinson WA, Bastian BC, Frieden IJ, Yeh I. Congenital melanocytic naevi initiated by BRAF fusion oncogene with firmness, pruritus and desmoplastic stroma. Br J Dermatol. 2025 Jul 17; 193(2):232-239.
-
Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov; 26(7):e503-e513.e11.
-
Lamoureux AA, Fisher MJ, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C, De Wilde B, Kazanowska B, Hutter C, Pfister SM, Sturm D, Jones DTW, Orbach D, Pierron G, Raskin S, Drilon A, Diamond EL, Harada G, Zapotocky M, Zamecnik J, Krskova L, Ellezam B, Weil AG, Venne D, Barritault M, Leblond P, Coltin H, Hammad R, Tabori U, Hawkins C, Hansford JR, Meyran D, Erker C, McFadden K, Sato M, Gottardo NG, Dholaria H, Nørøxe DS, Goto H, Ziegler DS, Lin FY, Parsons DW, Lindsay H, Wong TT, Liu YL, Wu KS, Franson AT, Hwang E, Aguilar-Bonilla A, Cheng S, Cacciotti C, Massimino M, Schiavello E, Wood P, Hoffman LM, Cappellano A, Lassaletta A, Van Damme A, Llort A, Gerber NU, Spalato Ceruso M, Bendel AE, Skrypek M, Hamideh D, Mushtaq N, Walter A, Jabado N, Alsahlawi A, Farmer JP, Coleman C, Mueller S, Mazewski C, Aguilera D, Robison NJ, O'Halloran K, Abbou S, Berlanga P, Geoerger B, Øra I, Moertel CL, Razis ED, Vernadou A, Ducray F, Bronnimann C, Seizeur R, Clarke M, Resnick AC, Alves M, Jones C, Doz F, Laetsch TW, Perreault S. Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
-
Malik F, Koo SC, Din NU, Tran QT, Lopez-Nunez O, Barresi S, Vallese S, Milano G, Miele E, Clay MR, Alaggio R, Orr BA. Reappraisal of soft tissue myoepithelial tumors by DNA methylation profiling reveals an epigenetically distinct group of mostly fusion-driven neoplasms. Virchows Arch. 2025 Mar; 486(3):573-584.
-
Reddy NK, Subbiah V. Redefining pancreatic cancer management with tumor-agnostic precision medicine. Carcinogenesis. 2024 Nov 22; 45(11):836-844.
-
Hsieh J, Danis EP, Owens CR, Parrish JK, Nowling NL, Wolin AR, Purdy SC, Rosenbaum SR, Ivancevic AM, Chuong EB, Ford HL, Jedlicka P. Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma. Oncogene. 2025 Jan; 44(1):19-29.
-
Chu YH, Kobrossy B, Schwartz D, Bruns AD, Marsh J. Secretory Carcinoma of the Thyroid: A Case Report and Update of Literature. Head Neck Pathol. 2024 Sep 22; 18(1):84.
-
Rheingold SR, Bhojwani D, Ji L, Xu X, Devidas M, Kairalla JA, Shago M, Heerema NA, Carroll AJ, Breidenbach H, Borowitz M, Wood BL, Angiolillo AL, Asselin BL, Bowman WP, Brown P, Dreyer ZE, Dunsmore KP, Hilden JM, Larsen E, Maloney K, Matloub Y, Mattano LA, Winter SS, Gore L, Winick NJ, Carroll WL, Hunger SP, Raetz EA, Loh ML. Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2024 Nov; 38(11):2382-2394.
-
Lee JC, Koo SC, Furtado LV, Breuer A, Eldomery MK, Bag AK, Stow P, Rose G, Larkin T, Sances R, Kleinschmidt-DeMasters BK, Bodmer JL, Willard N, Gokden M, Dahiya S, Roberts K, Bertrand KC, Moreira DC, Robinson GW, Mo JQ, Ellison DW, Orr BA. Concurrent ependymal and ganglionic differentiation in a subset of supratentorial neuroepithelial tumors with EWSR1-PLAGL1 rearrangement. Acta Neuropathol Commun. 2024 09 03; 12(1):143.
-
Johnson M, Willard N, Pan Z. Systemic ALK-negative anaplastic large cell lymphoma with NPM1::TYK2 rearrangement. J Hematop. 2024 Dec; 17(4):265-270.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|